methotrexate + vincristine + doxorubicin + prednisone

**Methotrexate + vincristine + doxorubicin + prednisone** is a combination chemotherapy regimen consisting of four distinct antineoplastic agents used primarily for the treatment of various lymphomas and leukemias. Methotrexate is a folate analog that inhibits dihydrofolate reductase, disrupting DNA synthesis; vincristine is a vinca alkaloid that binds tubulin to inhibit microtubule formation and mitosis; doxorubicin is an anthracycline that intercalates DNA and inhibits topoisomerase II; prednisone is a synthetic glucocorticoid that induces lymphoid apoptosis and suppresses inflammation. This multi-agent approach leverages non-overlapping toxicities and synergistic cytotoxicity to target rapidly proliferating malignant cells, commonly applied in aggressive B-cell lymphomas or acute lymphoblastic leukemia, though not established as a standard named protocol like CHOP or MOPP.